Exceeding Revenue and EPS Expectations
Total company operational sales grew 19% and organic sales grew 15%, exceeding guidance of 12% to 14%. Q3 adjusted EPS of $0.75 grew 19%, exceeding guidance range of $0.70 to $0.72.
Strong Regional Growth
U.S. operational growth was 27%, driven by Cardiovascular, Endoscopy, and Neuromodulation. Asia Pac grew 17% operationally, led by Japan and China.
WATCHMAN and EP Success
WATCHMAN grew 35% this quarter with over 600,000 patients treated. EP sales grew 63%, with strong adoption of FARAPULSE technology.
Improved Full Year Guidance
Raised full year '25 adjusted EPS guidance to $3.02 to $3.04, representing growth of 20% to 21%. Full year organic revenue growth guidance increased to approximately 15.5%.